Preferred Label : brexpiprazole;

MeSH synonym : 7-(4-(4-(1-benzothiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one;

UNII : 2J3YBM1K8C;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
brexpiprazole
brexpiprazole
drug approval
europe
schizophrenia
adult
administration, oral
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
antipsychotic agents
antipsychotic agents
drug evaluation, preclinical
thiophenes
quinolones
thiophenes
quinolones

---
Summary Basis of Decision (SBD) for Rexulti
Brexpiprazole 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg tablets, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00353
2017
false
false
false
Canada
French
drug information
brexpiprazole
brexpiprazole
drug approval
canada
treatment outcome
schizophrenia
antipsychotic agents
adult
aged
brexpiprazole
antipsychotic agents
tablets
administration, oral
thiophenes
quinolones
thiophenes
quinolones

---
Nous contacter.
27/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.